MRI-Guided radiation: a sharper weapon against prostate cancer?
NCT ID NCT00913939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new way to deliver high-dose radiation to prostate tumors using real-time MRI guidance. It includes two groups: men whose prostate cancer has returned after prior radiation, and men with advanced cancer receiving standard external beam radiation plus this boost. The goal is to see if MRI guidance improves accuracy and tumor targeting in up to 500 patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MRI-guided HDR brachytherapy
- What this could lead to
- If successful, this approach could make prostate cancer treatment more precise, potentially reducing side effects and improving outcomes for patients with recurrent or advanced disease.
- What could go wrong
- This is a pilot study focused on technical performance, not yet proven to improve survival. The procedure is complex and may carry risks like bleeding, infection, or urinary problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
May 2009
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Prior enrollment of UHN 05-0641-C or UHN 12-5015-C (Arm 1) * Histological evidence of recurrent prostate adenocarcinoma (Arm 1) * PSA doubling time \> 6 months (Arm 1) * Intermediate and High-risk localized prostate cancer (\>T1 or PSA\>10 or Gleason \> 6) (Arm 2) * Planned for EBRT + HDR boost (+/- hormone therapy) (Arm 2) * ECOG 0 or 1 * Age \> 18 years * Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed. Exclusion Criteria: * Radiological evidence of regional or distant metastases * Contraindications to MRI (Patient weight as per MRI Technologist's discretion, Patients with pacemakers, cerebral aneurysm clips, shrapnel injury, or implantable electronic devices not compatible with MRI) * Bleeding diathesis and anti-coagulative therapy that cannot be temporarily ceased during brachytherapy * Previous prostate brachytherapy * Active hormonal therapy at time of brachytherapy (Arm 1) * Previous pelvic radiotherapy (Arm 2) * Contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids or colorectal surgery. * Latex Allergy * Contraindications to conscious sedation, local anesthesia, or spinal/epidural anesthesia. * IPSS \>18 * Large TURP defect * TURP within the past 6 months * Prostate gland size \>80cc (Arm 2, whole gland HDR patients only) * History of Ulcerative Colitis and SLE (except for patients where the clinician determines benefit outweighs the risk of radiation) * Other medical conditions deemed by the PI to make patient ineligible for MRI-guided Prostate HDR brachytherapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally recurrent prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network, Princess Margaret Hospital
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.